CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to IVBXF

IBI351 combined with cetuximab β

Phase 2
Innovent Biologics Inc/ADR (IVBXF)

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Sep '27
IVBXFPhase 2

IBI351 combined with cetuximab β Phase 2 Est. Readout

IBI351 combined with cetuximab β
Sep 2027~
CT.gov
00%
Competitive Landscape

1 competitor in Lung Cancer (Non-Small Cell)

View Full Landscape
Drug Information

Target Indication

Lung Cancer (Non-Small Cell)

Clinical Trial

NCT07198841

Last updated: 10/3/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.